Drug

Ranibizumab

Approved medicine

ResearchOngoing research

Also known as Byooviz, Cimerli, Lucentis, RBZ+2 more

Byooviz, Cimerli, Lucentis, RBZ, Susvimo, rhuFab V2.

RxNorm595060UNIIZL1R02VT79

Research papers

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

CHMP positive opinion: Susvimo (EMA)

Regulatory2026-07-24EMA

Approval: Vislyfa (EMA)

Regulatory2026-07-15EMA

Approval: Rimmyrah (EMA)

Regulatory2024-01-05EMA

Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.

Research2017-07-25De Cillà S · Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Ranibizumab

Aliases & brands

ByoovizCimerliLucentisRBZSusvimorhuFab V2

RxNorm CUI

595060

UNII

ZL1R02VT79

Regulatory jurisdictions

ema

Regulatory timeline

3 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2024-01-05

Latest approval

2026-07-15

Authorities

EMA

Total events

emaEuropean Medicines Agency· 3 events

2026-07-24CHMP positive opinion

CHMP positive opinion: Susvimo (EMA)

Indication: Treatment of adults with neovascular (wet) age-related macular degeneration (AMD).

Evidence ↗

2026-07-15Approval

Approval: Vislyfa (EMA)

Indication: Vislyfa is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema… Show full indication

Vislyfa is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)

Evidence ↗

2024-01-05Approval

Approval: Rimmyrah (EMA)

Indication: Rimmyrah is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema… Show full indication

Rimmyrah is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2017 · 16 cites

Related drugs

5 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Adenine